Biricik Ebru, Hatipoğlu Zehra, Küçükbingöz Çağatay
Department of Anaesthesiology and Reanimation, Çukurova University School of Medicine, Adana, Turkey.
Turk J Anaesthesiol Reanim. 2016 Apr;44(2):99-101. doi: 10.5152/TJAR.2016.60973. Epub 2016 Apr 1.
Brugada Syndrome was first described in 1992 by Pedro Brugada as a genetic syndrome that is characterized by ventricular arrhythmias that may result in sudden cardiac arrest. In particular, a right bundle branch block and ST segment elevation in the right precordial leads are observed. Many perioperative pharmalogical and physiological factors can trigger malignant arrhythmias. Although it is a rare condition, the anaesthestic management of Brugada syndrome is important because of the potentially fatal complications. Many anaesthetics have been administered during the operation of patients with Brugada Syndrome. The use of sugammadex instead of the anaesthetic management of patients with Brugada syndrome is discussed in this study.
1992年，佩德罗·布鲁加达首次将布鲁加达综合征描述为一种遗传性综合征，其特征是室性心律失常，可能导致心脏骤停。特别是，可观察到右束支传导阻滞和右胸前导联ST段抬高。许多围手术期的药理和生理因素可引发恶性心律失常。虽然这是一种罕见疾病，但由于可能出现致命并发症，布鲁加达综合征的麻醉管理很重要。在布鲁加达综合征患者手术期间已使用了多种麻醉剂。本研究讨论了使用舒更葡糖而非对布鲁加达综合征患者进行麻醉管理的情况。
